Oragenics Inc. (NYSE American: OGEN) announced it will present at the upcoming Sequire Investor Summit 2026, scheduled for January 20–22, 2026, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. During the conference, the company plans to highlight its novel approach to addressing the significant unmet medical need in concussion and mild traumatic brain injury. This includes progress toward advancing its ONP-002 clinical program into Phase 2a studies, an area where no approved drug therapies currently exist, according to Oragenics Chief Executive Officer Janet Huffman.
The company’s lead candidate, ONP-002, is being advanced as a potential first-in-class treatment for concussion and mild traumatic brain injury. Oragenics is progressing ONP-002 through Phase 2a clinical trials in Australia, with U.S. Phase IIb trials planned to follow. The company’s intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders. Oragenics is committed to developing innovative therapies that address significant unmet medical needs in neurological care.
The announcement comes as the company prepares to engage with investors at the summit, where it will discuss its clinical progress and therapeutic approach. The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN. The full press release can be viewed at https://ibn.fm/Gn84M. The Sequire Investor Summit provides a platform for companies to present their developments to potential investors and industry stakeholders.
This presentation is significant because concussion and mild traumatic brain injury represent a substantial medical challenge without approved pharmaceutical treatments. The condition affects millions of people annually, particularly athletes, military personnel, and accident victims. Current management typically involves rest and symptom monitoring rather than targeted therapeutic intervention. Oragenics’ approach using intranasal delivery represents a novel method for potentially treating these conditions directly at the site of injury in the brain.
The company’s participation in the investor summit reflects its ongoing efforts to advance its clinical programs and secure support for further development. As a clinical-stage biotechnology company, Oragenics focuses on developing brain-targeted therapeutics through proprietary intranasal delivery technology. The upcoming presentation will provide investors with insights into the company’s progress and future plans for its lead candidate and broader platform technology.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Oragenics to Showcase Concussion Treatment Progress at Investor Summit.